Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.05 USD | -1.91% | -4.65% | -57.99% |
Financials (USD)
Sales 2024 * | 104M | Sales 2025 * | 125M | Capitalization | 101M |
---|---|---|---|---|---|
Net income 2024 * | -52M | Net income 2025 * | -35M | EV / Sales 2024 * | 1.13 x |
Net Debt 2024 * | 16.38M | Net Debt 2025 * | 13.37M | EV / Sales 2025 * | 0.92 x |
P/E ratio 2024 * |
-1.91
x | P/E ratio 2025 * |
-3.05
x | Employees | 330 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.84% |
Latest transcript on Akoya Biosciences, Inc.
1 day | -1.91% | ||
1 week | -4.65% | ||
Current month | -4.65% | ||
1 month | -54.24% | ||
3 months | -59.00% | ||
6 months | -53.51% | ||
Current year | -57.99% |
Managers | Title | Age | Since |
---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 17-06-30 |
Johnny Ek
DFI | Director of Finance/CFO | 49 | 23-03-19 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 15-10-31 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 21-09-15 |
Director/Board Member | 67 | 19-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.52% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 2.05 | -1.91% | 201,399 |
24-06-06 | 2.09 | +2.45% | 185,379 |
24-06-05 | 2.04 | +1.49% | 273,576 |
24-06-04 | 2.01 | -1.47% | 192,407 |
24-06-03 | 2.04 | -5.12% | 246,681 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.99% | 101M | |
+9.48% | 222B | |
+13.72% | 195B | |
+23.79% | 148B | |
+33.39% | 113B | |
+4.03% | 66.45B | |
+3.16% | 50.03B | |
-4.35% | 38.8B | |
-1.27% | 34.85B | |
+22.61% | 30.98B |
- Stock Market
- Equities
- AKYA Stock